JENTADUETO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JENTADUETO (JENTADUETO).
Jentadueto is a combination of linagliptin and metformin. Linagliptin inhibits DPP-4, increasing incretin levels (GLP-1, GIP) and enhancing glucose-dependent insulin secretion while suppressing glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
| Metabolism | Linagliptin: minimal metabolism, primarily excreted unchanged via bile and gut (enterohepatic circulation). Metformin: not metabolized, excreted unchanged by kidneys. |
| Excretion | Renal: linagliptin ~5% unchanged; metformin ~90% unchanged. Fecal: linagliptin ~80% (mostly unchanged). Biliary: minimal. |
| Half-life | Linagliptin: terminal t1/2 ~12 hours (long binding to DPP-4). Metformin: terminal t1/2 ~6.2 hours (renal impairment prolongs). |
| Protein binding | Linagliptin: ~75-89% (saturable binding to DPP-4). Metformin: negligible (<5% bound to plasma proteins). |
| Volume of Distribution | Linagliptin: Vd ~1.0 L/kg (extensive tissue distribution). Metformin: Vd ~0.6-1.1 L/kg (confined to blood and peripheral tissues). |
| Bioavailability | Linagliptin: ~30% oral. Metformin: ~50-60% oral (fasted). |
| Onset of Action | Linagliptin: DPP-4 inhibition within 1-2 hours. Metformin: glucose-lowering effect within 2-3 hours (oral). |
| Duration of Action | Linagliptin: ~24 hours (once-daily dosing). Metformin: up to 24 hours (extended-release component). |
| Molecular Weight | 472.49 |
Administered orally twice daily with meals. Initial dose: one tablet JENTADUETO 5 mg/500 mg or 5 mg/1000 mg; subsequent titration based on glycemic response. Maximum daily dose: linagliptin 5 mg, metformin 2000 mg.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if eGFR <30 mL/min/1.73 m². For eGFR 30-45 mL/min/1.73 m²: maximum metformin dose 1000 mg/day (e.g., JENTADUETO 5 mg/500 mg twice daily or 5 mg/1000 mg once daily). Assess renal function before initiation and at least annually. Discontinue if eGFR falls persistently below 30 mL/min/1.73 m². |
| Liver impairment | Avoid use in patients with hepatic impairment (Child-Pugh class A, B, or C) due to metformin component and risk of lactic acidosis. No specific dosing recommendations available. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years. Not recommended. |
| Geriatric use | Initiate at lower doses (e.g., JENTADUETO 5 mg/500 mg twice daily) with gradual titration to minimize gastrointestinal side effects. Monitor renal function closely, as elderly are more susceptible to decreased eGFR and lactic acidosis. |
| 1st trimester | Not recommended. Limited human data; animal studies show harm. Use only if benefit outweighs risk. |
| 2nd trimester | Not recommended. Due to the metformin component, risk of lactic acidosis in pregnancy; insufficient safety data for linagliptin. |
| 3rd trimester | Not recommended. Metformin crosses placenta; linagliptin unknown. Avoid, especially in cases of gestational diabetes with risk of lactic acidosis. |
Clinical note
Comprehensive clinical and safety monograph for JENTADUETO (JENTADUETO).
| Placental transfer | Metformin readily crosses the placenta; linagliptin likely crosses but human data are lacking. |
| Breastfeeding | Metformin is excreted in human milk in low amounts; linagliptin is not studied. Caution should be exercised, and alternative agents preferred during breastfeeding. |
■ FDA Black Box Warning
Lactic acidosis associated with metformin; avoid use in patients with renal impairment, acute congestive heart failure, etc.
| Serious Effects |
Severe renal impairment (eGFR < 30 mL/min/1.73 m²)Acute or chronic metabolic acidosis, including diabetic ketoacidosisHistory of hypersensitivity to metformin, linagliptin, or any componentLactation (due to metformin)
| Precautions | Lactic acidosis (metformin component), Pancreatitis (linagliptin component), Hypoglycemia when used with insulin secretagogues or insulin, Renal impairment (assess before and during therapy), Vitamin B12 deficiency (long-term metformin use) |
| Food/Dietary | Take with meals to minimize metformin GI upset. Avoid excessive alcohol (≥3 drinks/day) due to increased risk of lactic acidosis. No specific food restrictions for linagliptin. |
Loading safety data…
| Lactation Rating |
| L3 - Limited Data |
| Teratogenic Risk | Insufficient human data; animal studies show fetal toxicity at maternally toxic doses. Use in pregnancy only if benefit outweighs risk. Avoid in second and third trimesters due to potential for metformin-associated lactic acidosis in neonates. |
| Fetal Monitoring | Monitor renal function, blood glucose, and lactic acidosis symptoms. In pregnancy, watch for fetal growth and neonatal hypoglycemia. For mother: LFTs, B12 levels if long-term metformin use. |
| Fertility Effects | No known direct effect on fertility. Metformin may restore ovulation in women with PCOS due to improved insulin sensitivity, thereby improving fertility. |
| Clinical Pearls | JENTADUETO combines linagliptin (DPP-4 inhibitor) and metformin (biguanide). Assess renal function before initiation; contraindicated if eGFR < 30 mL/min/1.73 m². Monitor for lactic acidosis, especially in renal impairment, hypoxia, or alcohol use. Pancreatitis has been reported with DPP-4 inhibitors; discontinue if suspected. Consider dose adjustments with strong P-glycoprotein or CYP3A4 inducers (e.g., rifampin) due to linagliptin interaction. |
| Patient Advice | Take with meals to reduce gastrointestinal side effects from metformin. · Report symptoms of lactic acidosis (unexplained fatigue, muscle pain, abdominal discomfort, slow/irregular heartbeat) immediately. · Avoid excessive alcohol intake (increases risk of lactic acidosis). · Inform healthcare provider if you experience persistent severe abdominal pain (possible pancreatitis). · Monitor blood glucose regularly and carry a source of sugar for hypoglycemia, though risk is low unless combined with insulin or sulfonylureas. |